Table 2 Systemic therapy details of patients with advanced non-small cell lung cancer by year and age cohort
| Â | 2009 | 2011 | 2015 | 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|  | < 70 years (n = 311) | ≥70 years (n = 269) | p-value | < 70 years (n = 417) | ≥70 years (n = 361) | p-value | < 70 years (n = 485) | ≥70 years (n = 516) | p-value | < 70 years (n = 478) | ≥70 years (n = 488) | p-value |
First line treatment | 138 (44%) | 61 (23%) | 0.258 | 221 (53%) | 90 (25%) | < 0.001 | 245 (51%) | 144 (28%) | 0.002 | 249 (52%) | 146 (30%) | 0.032 |
% of first line treatments received Platinum doublet Single agent Targeted therapy Immunotherapy Other | 121 (88%) 15 (11%) 2 (1%) 0% 0% | 50 (82%) 11 (18%) 0% 0% 0% | 187 (85%) 8 (3%) 26 (12%) 0% 0% | 58 (65%) 12 (13%) 20 (22%) 0% 0% | 182 (74%) 4 (1%) 58 (24%) 1 (1%) 0% | 87 (60%) 12 (8%) 43 (30%) 2 (2%) 0% | 143 (57%) 1 (1%) 82 (33%) 20 (8%) 3 (1%) | 71 (48%) 4 (3%) 47 (32%) 23 (16%) 1 (1%) | ||||
Second line treatment | 82 (26%) | 32 (12%) | 0.408 | 143 (34%) | 47 (13%) | 0.833 | 96 (20%) | 48 (9%) | 0.797 | 131 (27%) | 55 (11%) | 0.146 |
% of second line treatments received Platinum doublet Single agent Targeted therapy Immunotherapy Other | 9 (11%) 27 (32.9%) 46 (56.1%) 0% 0% | 1 (3%) 11 (34%) 20 (63%) 0% 0% | 23 (16%) 42 (29%) 75 (52%) 2 (1%) 1 (1%) | 7 (15%) 13 (28%) 26 (55%) 0% 1 (2%) | 15 (16%) 31 (32%) 32 (33%) 16 (17%) 2 (2%) | 6 (13%) 16 (33%) 19 40%) 7 (14%) 0% | 22 (17%) 5 (4%) 32 (24%) 69 (53%) 2 (2%) | 3 (6%) 1 (2%) 18 (33%) 22 (60%) 0% | ||||
Third line treatment | 37 (12%) | 16 (6%) | 0.353 | 72 (17%) | 16 (4%) | 0.149 | 41 (8%) | 19 (4%) | 0.342 | 50 (10%) | 16 (3%) | 0.491 |
% of third line treatments received Platinum doublet Single agent Targeted therapy Immunotherapy | 3 (8%) 17 (46%) 17 (46%) 0% | 0% 6 (38%) 10 (62%) 0% | 7 (10%) 32 (44%) 33 (46%) 0% | 2 (13%) 8 (50%) 5 (31%) 1 (6%) | 4 (10%) 15 (36%) 11 (27%) 11 (27%) | 0% 9 (47%) 7 (37%) 3 (16%) | 12 (24%) 16 (32%) 11 (22%) 11 (22%) | 5 (31%) 2 (13%) 5 (31%) 4 (25%) | ||||